Research programme: mitochondrial disease therapeutics - Chondrial Therapeutics

Drug Profile

Research programme: mitochondrial disease therapeutics - Chondrial Therapeutics

Alternative Names: CTI-1601

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University; Wake Forest University School of Medicine
  • Developer Chondrial Therapeutics
  • Class Proteins
  • Mechanism of Action Frataxin protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Friedreich's ataxia

Most Recent Events

  • 03 Aug 2017 CTI-1601 receives Orphan Drug status for Friedreich's ataxia in USA
  • 08 Feb 2017 Chondrial Therapeutics in-licenses technology from Indiana University Research and Technology Corporation and Wake Forest University Health Sciences
  • 06 Feb 2017 Chondrial Therapeutics announces intention to submit NDA to the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top